BBSRC Invests $16M in Synthetic Biology Startup Fund | GenomeWeb

NEW YORK (GenomeWeb News) – The Biotechnology and Biological Science Research Council said today that it has provided £10 million ($16.1 million) to launch an investment fund that will fund early-stage companies in the UK that are focused on commercializing synthetic biology technologies.

The BBSRC said the private investment company Midven will manage the fund, which will provide investments, strategic support, and help startup companies leverage private capital. Midven's Rainbow Seed Fund specializes in supporting firms that spin out from publicly-funded research programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.